메뉴 건너뛰기




Volumn 61, Issue 6, 2012, Pages 821-828

A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia

Author keywords

[No Author keywords available]

Indexed keywords

ACOTIAMIDE; PLACEBO;

EID: 84859855819     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301454     Document Type: Article
Times cited : (197)

References (46)
  • 2
    • 0032615306 scopus 로고    scopus 로고
    • Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)
    • Stanghellini V. Three-Month Prevalence Rates of Gastrointestinal Symptoms and the Influence of Demographic Factors: Results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:20-8. (Pubitemid 29510674)
    • (1999) Scandinavian Journal of Gastroenterology, Supplement , vol.33 , Issue.231 , pp. 20-28
    • Stanghellini, V.1
  • 4
    • 77949263569 scopus 로고    scopus 로고
    • Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan
    • Okumura T, Tanno S, Ohhira M, et al. Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J Gastroenterol 2010;45:187-94.
    • (2010) J Gastroenterol , vol.45 , pp. 187-194
    • Okumura, T.1    Tanno, S.2    Ohhira, M.3
  • 5
    • 57449096143 scopus 로고    scopus 로고
    • The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire
    • Nakajima S. The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire. J Gastroenterol Hepatol 2008;23(Suppl 2):S186-92.
    • (2008) J Gastroenterol Hepatol , vol.23 , Issue.SUPPL. 2
    • Nakajima, S.1
  • 6
    • 77952743651 scopus 로고    scopus 로고
    • Functional dyspepsia impacts absenteeism and direct and indirect costs
    • Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010;8:498-503.
    • (2010) Clin Gastroenterol Hepatol , vol.8 , pp. 498-503
    • Brook, R.A.1    Kleinman, N.L.2    Choung, R.S.3
  • 7
    • 27744445389 scopus 로고    scopus 로고
    • American gastroenterological association technical review on the evaluation of dyspepsia
    • DOI 10.1053/j.gastro.2005.09.020, PII S0016508505018184
    • Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80. (Pubitemid 41597412)
    • (2005) Gastroenterology , vol.129 , Issue.5 , pp. 1756-1780
    • Talley, N.J.1    Vakil, N.B.2    Moayyedi, P.3
  • 9
    • 79953668479 scopus 로고    scopus 로고
    • Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia
    • Tack J, Janssen P. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Expert Opin Investig Drugs 2011;20:701-12.
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 701-712
    • Tack, J.1    Janssen, P.2
  • 11
    • 0033862522 scopus 로고    scopus 로고
    • Z-338 a newly synthesized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission
    • Nakajima T, Nawata H, Ito Y. Z-338 a newly synthesized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res 2000;36:69-81.
    • (2000) J Smooth Muscle Res , vol.36 , pp. 69-81
    • Nakajima, T.1    Nawata, H.2    Ito, Y.3
  • 12
    • 49749087225 scopus 로고    scopus 로고
    • Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats
    • Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008;20:1051-9.
    • (2008) Neurogastroenterol Motil , vol.20 , pp. 1051-1059
    • Seto, K.1    Sasaki, T.2    Katsunuma, K.3
  • 13
    • 77950503626 scopus 로고    scopus 로고
    • Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia 100mg t.i.d. is an optimal dosage
    • Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia 100mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-27.
    • (2010) Neurogastroenterol Motil , vol.22 , pp. 618-627
    • Matsueda, K.1    Hongo, M.2    Tack, J.3
  • 14
    • 60649100914 scopus 로고    scopus 로고
    • A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia
    • Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272-80.
    • (2009) Neurogastroenterol Motil , vol.21 , pp. 272-280
    • Tack, J.1    Masclee, A.2    Heading, R.3
  • 15
    • 46749088568 scopus 로고    scopus 로고
    • A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: Efficacy in a randomized, double-blind, placebo-controlled dose ranging trial
    • Talley N, Tack J, Kowalski D, et al. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology 2008;134:A157.
    • (2008) Gastroenterology , vol.134
    • Talley, N.1    Tack, J.2    Kowalski, D.3
  • 16
    • 77951962316 scopus 로고    scopus 로고
    • Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia
    • Tack J, Talley N, Kowalski D, et al. Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia. Gastroenterology 2008;134:16.
    • (2008) Gastroenterology , vol.134 , pp. 16
    • Tack, J.1    Talley, N.2    Kowalski, D.3
  • 17
    • 79951665389 scopus 로고    scopus 로고
    • Endpoints used in functional dyspepsia drug therapy trials
    • Ang D, Talley NJ, Simren M, et al. Endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-49.
    • (2011) Aliment Pharmacol Ther , vol.33 , pp. 634-649
    • Ang, D.1    Talley, N.J.2    Simren, M.3
  • 18
    • 0023232668 scopus 로고
    • A comparison of likert and visual analogue scales for measuring change in function
    • DOI 10.1016/0021-9681(87)90080-4
    • Guyatt GH, Townsend M, Berman LB, et al. A comparison of Likert and Visual Analogue Scales for measuring change in function. J Chronic Dis 1987;40:1129-33. (Pubitemid 17158144)
    • (1987) Journal of Chronic Diseases , vol.40 , Issue.12 , pp. 1129-1133
    • Guyatt, G.H.1    Townsend, M.2    Berman, L.B.3    Keller, J.L.4
  • 19
    • 0035074507 scopus 로고    scopus 로고
    • Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: A meta-analysis
    • DOI 10.1016/S0002-9270(00)02314-5, PII S0002927000023145
    • Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-96. (Pubitemid 32240716)
    • (2001) American Journal of Gastroenterology , vol.96 , Issue.3 , pp. 689-696
    • Veldhuyzen, V.Z.S.J.O.1    Jones, M.J.2    Verlinden, M.3    Talley, N.J.4
  • 21
    • 0037181736 scopus 로고    scopus 로고
    • Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial
    • Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-HP) randomised controlled trial. BMJ 2002;324:1012-16. (Pubitemid 34457514)
    • (2002) British Medical Journal , vol.324 , Issue.7344 , pp. 1012-1016
    • Chiba, N.1    Veldhuyzen, V.Z.S.J.O.2    Sinclair, P.3    Ferguson, R.A.4    Escobedo, S.5    Grace, E.6
  • 24
    • 49349102447 scopus 로고    scopus 로고
    • Tegaserod treatment for functional dyspepsia dysmotility symptoms: Results of two randomized, controlled trials
    • Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for functional dyspepsia dysmotility symptoms: results of two randomized, controlled trials. Am J Gastroenterol 2008;103:1906-19.
    • (2008) Am J Gastroenterol , vol.103 , pp. 1906-1919
    • Vakil, N.1    Laine, L.2    Talley, N.J.3
  • 25
    • 0033199083 scopus 로고    scopus 로고
    • Validity of a new quality of life scale for functional dyspepsia: A United States multicenter trial of the Nepean Dyspepsia Index
    • DOI 10.1111/j.1572-0241.1999.01363.x, PII S0002927099004190
    • Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United states multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999;94:2390-7. (Pubitemid 29420662)
    • (1999) American Journal of Gastroenterology , vol.94 , Issue.9 , pp. 2390-2397
    • Talley, N.J.1    Verlinden, M.2    Jones, M.3
  • 26
    • 0035126078 scopus 로고    scopus 로고
    • Quality of life in functional dyspepsia: Responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form
    • DOI 10.1046/j.1365-2036.2001.00900.x
    • Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new-10 item short form. Aliment Pharmacol Ther 2001;15:207-16. (Pubitemid 32142498)
    • (2001) Alimentary Pharmacology and Therapeutics , vol.15 , Issue.2 , pp. 207-216
    • Talley, N.J.1    Verlinden, M.2    Jones, M.3
  • 27
    • 49149121213 scopus 로고    scopus 로고
    • The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval
    • Burke LB, Kennedy DL, Miskala PH, et al. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008;84:281-3.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 281-283
    • Burke, L.B.1    Kennedy, D.L.2    Miskala, P.H.3
  • 28
    • 77950502427 scopus 로고    scopus 로고
    • Evolution of clinical trials for irritable bowel syndrome: Issues in end points and study design
    • Trentacosti AM, He R, Burke LB, et al. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 2010;105:731-5.
    • (2010) Am J Gastroenterol , vol.105 , pp. 731-735
    • Trentacosti, A.M.1    He, R.2    Burke, L.B.3
  • 30
    • 0032564656 scopus 로고    scopus 로고
    • Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia
    • Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group
    • Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81.
    • (1998) N Engl J Med , vol.339 , pp. 1875-1881
    • Blum, A.L.1    Talley, N.J.2    O'Morain, C.3
  • 31
    • 0024852022 scopus 로고
    • Measurement of health status. Ascertaining the minimal clinically important difference
    • DOI 10.1016/0197-2456(89)90005-6
    • Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15. (Pubitemid 20025670)
    • (1989) Controlled Clinical Trials , vol.10 , Issue.4 , pp. 407-415
    • Jaeschke, R.1    Singer, J.2    Guyatt, G.H.3
  • 32
    • 0036893791 scopus 로고    scopus 로고
    • Functional heartburn: The stimulus, the pain, and the brain
    • DOI 10.1136/gut.51.6.885
    • Fass R, Tougas G. Functional heartburn: the stimulus, the pain and the brain. Gut 2002;51:885-92. (Pubitemid 35408615)
    • (2002) Gut , vol.51 , Issue.6 , pp. 885-892
    • Fass, R.1    Tougas, G.2
  • 33
    • 27744571011 scopus 로고    scopus 로고
    • Guideline for the management of dyspepsia
    • Practice Parameters Committee of the American College of Gastroenterology
    • Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guideline for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-37.
    • (2005) Am J Gastroenterol , vol.100 , pp. 2324-2337
    • Talley, N.J.1    Vakil, N.2
  • 36
    • 44149124107 scopus 로고    scopus 로고
    • Itopride in functional dyspepsia: Results of two phase III multicentre, randomised, double-blind, placebo-controlled trials
    • DOI 10.1136/gut.2007.132449
    • Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two Phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-6. (Pubitemid 351716964)
    • (2008) Gut , vol.57 , Issue.6 , pp. 740-746
    • Talley, N.J.1    Tack, J.2    Ptak, T.3    Gupta, R.4    Giguere, M.5
  • 37
    • 0013418378 scopus 로고    scopus 로고
    • A Phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastoric emptying
    • Tack J, Delia T, Ligozio G, et al. A Phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastoric emptying. Gastroenterology 2002;122:154.
    • (2002) Gastroenterology , vol.122 , pp. 154
    • Tack, J.1    Delia, T.2    Ligozio, G.3
  • 40
    • 66949172842 scopus 로고    scopus 로고
    • Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia
    • Jones M, Talley NJ. Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia. Am J Gastroenterol 2009;104:1483-8.
    • (2009) Am J Gastroenterol , vol.104 , pp. 1483-1488
    • Jones, M.1    Talley, N.J.2
  • 42
    • 45849137830 scopus 로고    scopus 로고
    • Tegaserod withdrawal from the world market. A treatment for constipation with cardiovascluar adverse effect
    • Anon.
    • Anon. Tegaserod withdrawal from the world market. A treatment for constipation with cardiovascluar adverse effect. Prescrire Int 2008;17:112-13.
    • (2008) Prescrire Int , vol.17 , pp. 112-113
  • 44
    • 79953666705 scopus 로고    scopus 로고
    • Z-338 improves meal-induced symptoms in Functional Dyspepsia: A double-blind, randomized, placebo controlled crossover study
    • Adam B, Liebregts T, Zschau N, et al. Z-338 improves meal-induced symptoms in Functional Dyspepsia: a double-blind, randomized, placebo controlled crossover study. Gastroenterology 2009;136:A535.
    • (2009) Gastroenterology , vol.136
    • Adam, B.1    Liebregts, T.2    Zschau, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.